Synaptic Therapeutics is a clinical-stage biotechnology company focused on developing novel therapeutics that protect and restore synaptic function in neurodegenerative diseases. Founded in 2021 and headquartered in Cambridge, Massachusetts, the company's mission is to address synaptic loss, the strongest pathological correlate of cognitive decline in Alzheimer's disease["@synaptic"].
...
Overview
Mermaid diagram (expand to render)
Synaptic Therapeutics is a clinical-stage biotechnology company focused on developing novel therapeutics that protect and restore synaptic function in neurodegenerative diseases. Founded in 2021 and headquartered in Cambridge, Massachusetts, the company's mission is to address synaptic loss, the strongest pathological correlate of cognitive decline in Alzheimer's disease["@synaptic"].
The company's lead program, ST-101, is a first-in-class small molecule that targets the sigma-2 receptor to protect synapses from amyloid-beta toxicity. Unlike amyloid-targeting antibodies that aim to reduce amyloid burden, ST-101 directly protects the synaptic connections that are essential for memory and cognition.
Pipeline Overview
| Program | Target/Mechanism | Indication | Phase | Status | |---------|-----------------|------------|-------|--------| | ST-101 | Sigma-2 receptor agonist | Alzheimer's disease | Phase 1 | Active (2024) | | ST-202 | Sigma-2 receptor agonist | Parkinson's disease | Preclinical | Research | | ST-303 | Synaptic stabilizer | Dementia with Lewy Bodies | Discovery | Research |
Technology Platform
Sigma-2 Receptor Targeting
Synaptic Therapeutics focuses on the sigma-2 receptor:
Receptor Function:
Located on endoplasmic reticulum and lysosomes
Regulates synaptic protein homeostasis
Controls autophagy and cellular stress responses
Protects against apoptosis
Therapeutic Approach:
Direct synaptic protection
Independent of amyloid reduction
Preserves dendritic spine integrity
Maintains neuronal connectivity
Synaptic Protection Mechanism
ST-101 protects synapses through multiple pathways:
Prevents Synaptic Loss:
Blocks amyloid-beta induced synapse damage
Maintains dendritic spine density
Preserves postsynaptic structures
Enhances Cellular Resilience:
Activates stress protective pathways
Improves protein homeostasis
Reduces apoptotic signaling
Supports Neural Function:
Maintains neurotransmitter release
Preserves synaptic plasticity
Protects against excitotoxicity
Lead Program: ST-101
Clinical Development
Phase 1 Study (2024):
ST-101 entered Phase 1 clinical trials in 2024, evaluating: